GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,003 DKK | -0.45% |
|
+2.93% | -7.05% |
| 05-03 | GENMAB : A good start to 2024; guidance unchanged |  |
| 05-03 | Genmab Posts Q1 Net Profit Surge; Revenue Jumps | MT |
| Sales 2024 * | 19.8B 2.86B 228B | Sales 2025 * | 23.62B 3.41B 272B | Capitalization | 129B 18.68B 1,492B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.68B 676M 53.99B | Net income 2025 * | 6.63B 957M 76.44B | EV / Sales 2024 * | 5.17 x |
| Net cash position 2024 * | 27.03B 3.9B 312B | Net cash position 2025 * | 32.17B 4.65B 371B | EV / Sales 2025 * | 4.12 x |
| P/E ratio 2024 * |
29.1
x | P/E ratio 2025 * |
21.1
x | Employees | 2,286 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab A/S
More recommendations
More press releases
More news
| 1 day | -0.45% | ||
| 1 week | +2.93% | ||
| Current month | +2.38% | ||
| 1 month | -2.20% | ||
| 3 months | +4.60% | ||
| 6 months | -8.75% | ||
| Current year | -7.05% |
1 week
1 988.00
2 056.00
1 month
1 915.502 122.00
Current year
1 825.002 227.00
1 year
1 825.002 939.00
3 years
1 825.003 327.00
5 years
1 078.003 327.00
10 years
180.103 327.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.64% | 0 M€ | +16.95% | ||
| 1.28% | 0 M€ | +9.46% | ||
| 1.01% | 0 M€ | +0.69% | ||
| 0.75% | 0 M€ | +7.69% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/05/24 | 2,003 | -0.45% | 98,861 |
| 07/05/24 | 2,012 | +0.40% | 98,188 |
| 06/05/24 | 2,004 | -2.77% | 103,761 |
| 03/05/24 | 2,061 | +5.91% | 200,097 |
| 02/05/24 | 1,946 | -0.99% | 109,856 |
Delayed Quote Nasdaq Copenhagen, May 08, 2024 at 03:59 pm
More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
01/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,003
DKK
Average target price
2,470
DKK
Spread / Average Target
+23.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.05% | 18.68B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B | |
| +295.70% | 8.12B |
- Stock Market
- Equities
- GMAB Stock
